Activation of Cutaneous Protein Kinase Cα Induces Keratinocyte Apoptosis and Intraepidermal Inflammation by Independent Signaling Pathways

Christophe Cataisson, Elizabeth Joseloff, Rodolfo Murillas, Alice Wang, Coralyn Atwell, Sara Torgerson, Michael Gerdes, Jeffrey Subleski, Ji-Liang Gao, Philip M. Murphy, Robert H. Wiltrout, Charles Vinson and Stuart H. Yuspa

*J Immunol* 2003; 171:2703-2713; doi: 10.4049/jimmunol.171.5.2703

http://www.jimmunol.org/content/171/5/2703

**Why *The JI*?**

- **Rapid Reviews! 30 days** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Speedy Publication!** 4 weeks from acceptance to publication

*average

**References**

This article **cites 63 articles**, 32 of which you can access for free at: http://www.jimmunol.org/content/171/5/2703.full#ref-list-1

**Subscription**

Information about subscribing to *The Journal of Immunology* is online at: http://jimmunol.org/subscription

**Permissions**

Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**

Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Activation of Cutaneous Protein Kinase Cα Induces Keratinocyte Apoptosis and Intraepidermal Inflammation by Independent Signaling Pathways

Christophe Cataisson,* Elizabeth Joseloff,1* Rodolfo Murillas,2* Alice Wang,* Coralyn Atwell,* Sara Torgerson,* Michael Gerdes,* Jeffrey Subleski, ‡ Ji-Liang Gao, § Philip M. Murphy, § Robert H. Wiltrout, ‡ Charles Vinson, ‡ and Stuart H. Yuspa 3*

Skin keratinocytes are major mediators of host immune responses. The skin is also a target for immunologically based inflammation in many pathological states. Activation of protein kinase C (PKC) can induce cutaneous inflammation, but the precise role of each of six cutaneous PKC isoforms (α, δ, ε, η, ζ, μ) that regulate normal skin homeostasis or contribute to skin pathology has not been clarified. We generated transgenic mice that overexpress PKCα in the basal layer of the epidermis and the outer root sheath of hair follicles under the regulation of the bovine keratin 5 promoter. K5-PKCα transgenic mice exhibit severe intraepidermal neutrophilic inflammation and disruption of the epidermis and upper hair follicles when treated topically with 12-O-tetradecanoylphorbol-13-acetate (TPA). Both TPA and UVB cause apoptosis in transgenic skin, but only TPA evokes intraepidermal inflammation. TPA also induces apoptosis in cultured transgenic keratinocytes, and this is prevented by an AP-1 dominant-negative construct. However, inhibiting AP-1 in vivo does not abrogate intraepidermal inflammation. Transcripts for specific cytokines and chemokines are elevated in TPA-treated cultured transgenic keratinocytes, and conditioned culture medium from these cells promotes neutrophil migration in vitro. Chemokine expression and neutrophil migration are not diminished by inhibiting AP-1. Thus, PKCα activation induces keratinocyte apoptosis via an AP-1-dependent pathway and mediates chemokine induction and intraepidermal inflammation independently. This model system will be useful to define specific chemokines regulated by PKCα that promote intraepidermal neutrophilic inflammation, a condition that characterizes several human cutaneous diseases such as pustular psoriasis and acute generalized exanthematous pustulosis. The Journal of Immunology, 2003, 171: 2703–2713.

A number of studies have indicated that protein kinase C (PKC) isoforms contribute to the regulation of skin homeostasis (1), and alterations in PKC signaling are fundamental to the pathogenesis of cutaneous diseases, including hyperproliferative, inflammatory, and neoplastic lesions (2–4). Analyses of both rodent and human epidermal reveal that six isoforms of PKC are expressed in keratinocytes (α, δ, ε, η, ζ, μ). The challenge, then, is to determine the contribution of each isoform to normal regulation or disease pathogenesis in the hope that specific agonists or antagonists will become useful pharmaceuticals in cutaneous therapy.

Several laboratories have addressed the contribution of PKC isoforms to the regulation of growth and differentiation of normal keratinocytes. PKC activity is required for expression of epidermal differentiation markers (5–8), and the expression level and intracellular distribution of individual PKC isoforms are modified during keratinocyte maturation (9). Specifically, PKCζ increases during the late stages of epidermal differentiation in vitro and in vivo, and this isoform induces the expression and activation of transglutaminase 1 when overexpressed in cultured keratinocytes (10, 11). PKCδ also activates transglutaminase 1 when overexpressed, and induces a keratinocyte death pathway mediated through mitochondrial targeting (10, 11). PKCα activity is necessary for the expression of loricrin, filaggrin, surface plasmon resonance (SPR)-1, and transglutaminase 1 in cultured mouse keratinocytes and suppresses keratins 1 and 10 in the granular layer of the epidermis (5, 6). Furthermore, PKCα regulates the expression of specific AP-1 factors that are associated with particular stages of epidermal differentiation (12, 13). The relationship of PKCα to AP-1 activity in skin extends to neoplastic development where the aberrant expression of differentiation markers detected in keratinocytes transformed by a v-ras oncogene is attributed to increased activity of PKCα and activation of AP-1 transcription factors (14).

Most of the foregoing studies were conducted in vitro using intact or transfected cultured human or mouse keratinocytes induced to differentiate under varying culture conditions, sometimes in the presence of PKC inhibitors. More recently, PKCα, δ, and ε have been transgenically targeted to the epidermis of FVB/N mice with the keratin 14 promoter producing distinct phenotypic changes (15–17). Although undisturbed skin was normal in PKCα

---

*Laboratories of Cellular Carcinogenesis and Tumor Promotion, †Metabolism, and 2Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892

Received for publication May 9, 2003. Accepted for publication June 27, 2003.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Current address: Celera Genomics, Rockville, MD 20850.
2 Current address: Departamento de Biologia Molecular y Celular, Centro de Investigaciones Energéticas Medioambientales, y Tecnológicas, Madrid, 28040 Spain.
3 Address correspondence and reprint requests to Dr. Stuart H. Yuspa, Laboratory of Cellular Carcinogenesis and Tumor Promotion, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, MSC-4255, Building 37, Room 4068, Bethesda, MD 20892-4255. E-mail address: yuspas@mail.nih.gov

4 Abbreviations used in this paper: PKC, protein kinase C; TPA, 12-O-tetradecanoylphorbol-13-acetate; SPR, surface plasmon resonance; COX-2, cyclooxygenase-2; BrdU, 5-bromo-2’-deoxyuridine; DAPI, 4’,6’-diamidino-2-phenylindole; MIP, macrophage-inflammatory protein; RPA, RNase protection assay; TRE, TPA response element.
PKCs MEDIATES INTRAEPIDERMAL INFLAMMATION

or δ mice, PKCε mouse epidermis was slightly hyperplastic (17), suggesting this isoform contributes to keratinocyt e proliferation. When the PKC activator 12-O-tetradecanoylphorbol-13-acetate (TPA) was applied to transgenic skin, sustained hyperplasia was greatest in PKCε epidermis, confirming a proliferative influence of this isoform. Major differences among the three transgenic lines were detected in skin tumor induction studies using 7,12-dimethyl-benz[a]anthracene as initiator and TPA as the promoter. K14-PKCS mice developed few papillomas or carcinomas, whereas K14-PKCa mice were very sensitive to carcinoma formation, developing malignant tumors even in the absence of TPA application (16, 17). K14-PKCa transgenic mice did not differ from nontransgenic mice in tumor yield (15). Wang and Smart (18) developed K5-PKCa transgenic mice on a C57Bl/6 background and demonstrated that skin tumor formation was not influenced by overexpression of PKCa. However, TPA treatment of the K5-PKCa mice caused severe intraepidermal and dermal inflammation, degeneration of hair follicles, and a disruption and sloughing of the epidermis (18), changes not detected in the other PKC transgenic strains. This suggested that PKCa was influencing the inflammatory response in skin, and subsequent studies suggested this was mediated, at least in part, by PG generated through activation of phospholipase A2, and up-regulation of cyclooxygenase-2 (COX-2) (19).

We have developed FVB/N transgenic mice that overexpress PKCa in the basal layer of the epidermis and the outer-root sheath of the hair follicle under targeted expression of the keratin 5 promoter. These mice had the identical acute inflammatory response and epidermal degeneration after TPA activation as the C57BL/6 mice described by Wang and Smart. Because marked intraepidermal inflammation is an unusual response in mice, but has been seen in some human cutaneous diseases (20), we undertook a combined in vivo and in vitro analysis of transgenic skin and keratinocytes to determine which responses were primary to PKCa activity in keratinocytes, as opposed to secondary responses to the inflammatory infiltrates. We show that divergent signal transduction pathways emanating from PKCa regulate keratinocyte cell death and cutaneous inflammation, and therefore, PKCa or a downstream pathway may serve as a target for the treatment of certain inflammatory or cytotoxic skin diseases.

Materials and Methods
Plasmid construction and generation of transgenic mice
Full-length murine PKCa cDNA was excised from PKCa-pcDNA by partial digestion with Nhel and inserted in the Nhel site of plasmid p368 (21), which contains the bovine keratin K5 regulatory sequence, the second intron of the rabbit β-globin gene, and polyadenylation sequences kindly provided by Dr. J. Jorcano (Centro de Investigaciones Energéticas Medioambientales, y Tecnológicas, Madrid, Spain) (22). From this plasmid, designated K5-PKCa, the transgene was excised by digestion with AcoI and purified by agarose electrophoresis and EtT Tip columns (Schleicher & Schuell, Keene, NH), adjusted to a final concentration of 2 μg/ml, and microinjected into the pronuclei of FVB/N mouse embryos. Founder mice were identified by Southern blotting of 10 μg of genomic DNA from tail biopsies, digested with EcoRI, separated on a 0.8% agarose gel, and trans- ferred to a nylon membrane. The probe was a 4.5k/B/Nhel (5–9 kb) fragment from the K5-PKCa construct that corresponds to the keratin K5 regulatory region and the β-globin intron. Subsequent offspring were identified by PCR using primers TGCATAATAATTCTGGCTGGCG and GCATGAA-AP-1 DNA binding) (25) in vivo in K5-PKCa-expressing mice, a regulated

and targeted A-FOS mouse line was used. This line uses the tetracycline transactivator under regulation of the keratin 5 promoter sequences (26), which has been crossed into an A-FOS line with conditional expression controlled by the tetracycline ope (M. J. Gerdes, J. Mollia, M. R. Levy, A. Glick, S. H. Yuspa, and C. Vinson, manuscript in preparation). Mice expressing both the dominant-negative PKCa (A-FOS) and the PKCa transgenes were produced by crossing a double transgenic A-FOS (K5-TA/tet-O-A-FOS) and K5-PKCa. At weaning, tail samples were collected and screened by three separate PCRs for each of the transgenes, and the triple transgenic mice were used for TPA treatment.

Cell culture
Primary mouse keratinocytes and hair follicle buds were isolated from newborn transgenic and wild-type littermate epidermis as described (27). Primary keratinocytes were seeded at a density of 5 × 10^5 cells per 60-mm dish (or equivalent concentrations) in Ca\(^{2+}\)- and Mg\(^{2+}\)-free MEM (Life Technologies, Rockville, MD) supplemented with 8% Chexle (Bio-Rad, Richmond, CA), treated FBS (Gemini Bio-Products, Woodland, CA), and 0.2 mM Ca\(^{2+}\). After 24 h, cultures were switched to the same medium with 0.05 mM Ca\(^{2+}\) to select for basal cells. TPA was reconstituted in DMSO, and primary keratinocytes were treated with TPA at varying concentrations and for various times as indicated in individual experiments.

Chemotaxis assays
Chemotaxis assays were performed using 48-well chemotaxis chambers (NeuroProbe, Cabin John, MD) as described previously (24). A total of 26–28 μl of conditioned medium collected at different time points after TPA treatment of cultured keratinocytes was placed in the wells of the lower compartment of the chamber, and 50 μl of mouse peritoneal neutrophils (1.5 × 10^6) were placed in the wells of the upper compartment. The upper and lower compartments were separated by a polyvinylpyrrolidone-free polycarbonate membrane (3-μm pore size; NeuroProbe). The pore size was chosen to allow the migration of neutrophils, but not monocytes. After incubation at 37 °C for 1 h, the filters were removed, washed on the upper side, and stained. Cells migrating across the filters were counted under light microscopy after the samples were coded. The results were expressed as a chemotaxis index, which represents the fold increase in the number of migrated cells in six high-powered fields in response to TPA stimulated supernatants over the spontaneous cell migration in response to control medium.

In vivo UVB irradiation of mice
Age-matched adult mice were irradiated with 2000, 3000, or 4000 J/m^2 UVB generated from four Westinghouse FS20 Sunlamp bulbs (270–385 nM emission spectrum with peak at 313 nM). The irradiated area was confined to a dorsal region by placement of a template that shielded unirradiated skin. The energy emitted by the lamps was measured with a model PMA 2100 meter (Solar Light, Philadelphia, PA) and a model PMA 2106 UV radiation detector calibrated to register the energy from 282 to 326 nm. Irradiated skin was harvested at 24 or 48 h, fixed in neutral formalin, and stained with H&E or assayed for apoptotic cells.

Immunohistochemistry and immunofluorescence
Shaven transgenic and wild-type animals were treated topically with a single dose (2 μg) of TPA in 200 μl of acetone. Skin was excised at various times after treatment and fixed in zinc fixative (BD PharMingen, San Di- ego, CA) or 10% formalin solution (Sigma-Aldrich, St. Louis, MO), par- af lin embedded, sectioned, and stained with H&E. Serial sections were incubated with rabbit anti-human T cell CD3 affinity purified Ab (Dako, Carpinteria, CA), rat anti-mouse F4/80 mAb to identify murine macro- phages (Serotec, Oxford, UK), or biotinylated rat mAb Ly-6G to detect peripheral neutrophils (Caltag Laboratories, Burlingame, CA). PKCa was detected in ethanol-fixed skin sections and methanol:acetone-fixed cultured cells using a mouse mAb against human PKCa (Sigma-Aldrich) and an anti-mouse IgG coupled to FITC (Vector Laboratories, Burlingame, CA). Cultured keratinocytes were pulsed for 1 h with 25 μM 5-bromo-2’-deoxyri- china (BrUdU) and fixed in methanol:acetone (1:1). Cultures were incub- ated with a mouse monoclonal anti-BrdU Ab (BD Biosciences, San Jose, CA) followed by a secondary biotinylated anti-mouse Ab (Jackson ImmunoResearch Laboratories, West Grove, PA). Immunoreactivity was detected using the ABC and DAB kits from Vector Laboratories. BrdU incorporation was quantitated by counting BrdU-labeled nuclei in 100 cells from three randomly chosen areas. Experiments were repeated three times. For 4’-6’-diamidino-2-phenylindole (DAPI) staining, a mounting medium with DAPI (Vector Laboratories) was used under coverslips overlaying fixed cells in situ. Fluorescence was detected with a Leitz DMRB microscope.
RT-PCR
RNA was isolated from cultured keratinocytes with TRRzol (Invitrogen, San Diego, CA). For cDNA synthesis, 1 μg of total RNA was reverse-transcribed using SuperScript II Reverse Transcriptase (Invitrogen). PCR amplifications were performed in a volume of 20 μl using Platinum PCR SuperMix (Invitrogen). The primers used for this analysis were as follows: GAPDH forward sequence, ATG GTG AAG GTC GGT AGG AAC G; GAPDH reverse sequence, ACC TGG TCC TCA GTG TACG CCA; macrophage inflammatory protein (MIP)-2 forward sequence, CTG CCA GCT CCT CAG TGC TGC ACT G; MIP-2 reverse sequence, TCC CGT CTT TGC ATG TTC TGG; CCR1 forward sequence, GCA GAA ACA AAT ACA CTC AG; COX-2 forward sequence, CAC AGT ACA CAT CCA GAC C; COX-2 reverse sequence TCC CGT CTT CTG AGT CTG CGT TCC CGT; GAPDH reverse sequence, ACC TGG TCC TCA GGA AGC AGC AAC TAC; MIP-3α reverse sequence, CTG TGT CCA ATT CTA TCC CAA AAA; TNF-α forward sequence, ATG AGC ACA GAA AGC ATG ATC CG; TNF-α reverse sequence GTA AGC ACT CAA AAG TAG ACC TGC CC. To avoid saturation or the plateau effect of amplification, PCR was limited to a total of 20 cycles for GAPDH and MIP-3α, 28 cycles for MIP-2, COX-2, and TNF-α, and 30 cycles for CCR1. Each reaction was performed from three independent experiments.

RNase protection assay (RPA)
RPAs were performed using Riboquant Transcription and RPA kit (BD PharMingen) according to manufacturer’s instructions with the following modifications. The labeled Multiprobe templates (BD PharMingen) and Mig 416 probes were purified using a g50 spin column (Amersham Pharmacia Biotech, Piscataway, NJ). RNase inactivation and precipitation were performed with a master mixture containing 200 μl of Ambion RNase inactivation reagent, 50 μl of ethanol, and 1 μl of Ambion GytocBlue per RNA sample. After the individual RNase-treated samples were added to 250 μl of the inactivation/precipitation mixture, the samples were mixed well, placed at −20°C for 30 min, and centrifuged at 20,800×g for 15 min. The supernatants were decanted, a sterile cotton swap was used to remove excess liquid, and the pellet was resuspended in 5 μl of BD PharMingen sample buffer. For all RPAs, the protected bands were separated on Acropoly 250 well, cultured for 3 days, and treated in triplicate with various doses of TPA for 6 h. To determine cell number, keratinocytes were trypsinized and counted using a Z series Coulter counter. Cell viability was determined after 18 h of TPA treatment by MTT assay using a cell proliferation assay. The results represent the mean of three independent experiments.

Assays of TRE-luciferase activity
TRE-luciferase activity was measured in primary keratinocytes isolated from K5-PKCα2×TRE-Luc and wild-type2×TRE-Luc bigenic mice. Cells were treated with TPA or DMSO for the indicated period of time; then, total cell extracts were prepared according to manufacturer’s protocol (Clontech Laboratories, Palo Alto, CA). Relative light units were normalized to protein determined by the Bradford protein assay (Bio-Rad). Results are expressed as fold increase of luciferase activity in TPA treated over respective control.

EMSA
Nuclear extracts (4 μg) were incubated with a 32P-labeled double-stranded probe containing the AP-1 consensus sequence (Promega) as described previously (28).

Adenovirus infection
A dominant-negative AP-1 vector, A-FOS, was introduced into keratinocytes using an adenoviral construct driven by a CMV promoter (25, 29), and empty adenovirus was used as control. The cells were infected for 30 min in serum-free medium with a multiplicity of infection of five viral particles per cell and 2.5 μg/ml Polybrene (Sigma-Aldrich) to enhance uptake. Serum containing medium was added to the cells for the next 48 h after the infection.

Results
PKCα mediates massive intraepidermal inflammation and sloughing in vivo
To generate a skin-targeted PKCα transgenic mouse, murine PKCα cDNA was cloned under the regulation of the keratin 5 promoter (Fig. 1A). Transgenic mice were generated using the FVB/N mouse strain, and several founder lines were developed expressing the transgene at high (10-fold) or moderate (3- to 5-fold) levels over the endogenous expression as shown by Southern and Western blot analysis. The plasmid construct used to generate PKCα transgenic mice contains the rabbit β-globin intron that can be detected in transgenic DNA by Southern analysis (Fig. 1B) and by PCR (Fig. 1C). Specific overexpression of the PKCα isoform could be seen in the skin and cultured keratinocytes by Western analysis and did not alter the level of other PKC isoforms in keratinocytes (Fig. 1, D and E). Localization of the PKCα transgene appeared to be targeted to the basal layer of the epidermis and the outer root sheath of the hair follicle as expected by keratin 5 expression (Fig. 2A). In cultured transgenic keratinocytes, PKCα was detected in the cytoplasm and more intensely in the perinuclear area as determined by immunofluorescence (Fig. 2B).

There were no abnormalities in the development of the transgenic animals compared with wild-type littermates, and the untreated epidermis appeared normal. However, the high-expressing PKCα transgenic animals were very sensitive to a single topical treatment of TPA to the skin. The moderate expressing lines were also TPA sensitive, but the changes described below were more focal than general. Subsequent experiments were performed on the high expressing line. As early as 12 h after TPA treatment, there was a severe inflammatory response in the skin of PKCα transgenic mice that was associated with a disruption of the epidermis...
FIGURE 1. Generation of transgenic mice overexpressing PKCα under the regulation of the keratin 5 promoter. A, For generating the transgene construct for skin-targeted PKCα transgenic mice, PKCα cDNA was microinjected into the pronuclei of FVB/N mouse embryos. B, DNA isolated from the tails of several founder transgenic and wild-type mice was digested with EcoRI and analyzed by Southern blotting with a probe for the bovine K5 promoter regulatory region. C, The transgene can be detected by PCR using primers to the β-globin intron of the transgene construct. WT = wild type; MW = molecular weight. D, Western analysis for PKCα protein expression can be detected from the skin of several different transgenic founder mice as well as nontransgenic mice. E, Primary keratinocytes isolated from a high expresser line of transgenic mice specifically overexpress PKCα in vitro, but not other isoforms as determined by Western blots of cell lysates.

A time course indicated that the inflammatory cells migrated rapidly out of dermal vessels and into the upper dermis around hair follicles within 6 h. By 12 h there is marked inflammation in the follicles and epidermis with the formation of micro-abscesses. Destruction of the epidermis and the upper hair follicles is observed by 12–18 h. The region of the follicle below the sebaceous gland is largely spared. By 24–48 h, the epidermal compartment is composed of inflammatory cells encapsulated by a stratum corneum. This inflammatory response is very similar to the phenotype described by Wang and Smart (18) for K5 PKCα transgenic mice on a C57BL/6 background. A series of leukocyte-selective Abs was used for immunohistochemistry on serial sections (Fig. 3B), revealing that neutrophils (Ly-6G-positive cells) are the predominant inflammatory component of the acute reaction in the follicles and epidermis of transgenic mice. Neutrophils can also be seen trafficking through the dermis of both wild-type and transgenic animals, but significant epithelial targeting is confined to the transgenic skin. Immunohistochemical staining for macrophages (F4/80-positive cells) or T cells (CD-3− cells) in serial sections did not reveal an accumulation of these cell types (data not shown) within the first 48 h.

Remarkably, the massive and uniform destructive consequences of a single low dose TPA exposure on transgenic skin did not cause any apparent adverse effect on the host. By 3 days after treatment, there is almost complete regeneration of the epidermis, and over the next several days there is a marked hyperplastic response in the epidermis and regeneration of the hair follicles (Fig. 3A). Thus, a protected population of regenerative, multipotential cells below the level of the sebaceous gland must respond rapidly to the destruction of the superficial epithelial components of the skin.

Loss of keratinocyte viability is a consequence of activation of PKCα independent of the inflammatory infiltrate

TUNEL assays revealed that apoptosis of the epidermis and upper hair follicle could be detected as early as 6 h after TPA application to transgenic skin, before the major infiltration of neutrophils was seen (Fig. 4D). A greater number of keratinocytes were positively stained by 12 h, but the infiltration of neutrophils at that time made it difficult to distinguish cell types definitively. Apoptotic keratinocytes were mostly absent from TPA-treated wild-type epidermis (Fig. 4C). To determine whether the intraepidermal inflammatory infiltrate is a nonspecific consequence of the apoptosis, transgenic mice were irradiated with either 2000, 3000, or 4000 J/M2 UVB, and their skin was examined for apoptotic cells (Fig. 4, A and B). Although a substantial number of apoptotic cells were detected at 24 h, the inflammatory response was confined to the dermal compartment (Fig. 4, E and F). This suggests that the intraepidermal inflammatory response to TPA is a specific consequence of PKCα activation, and not a general response to cell killing, but it does not exclude the possibility that apoptosis is secondary to inflammation.

To distinguish inflammation-independent effects of PKCα activation on the viability of epidermal and upper follicle cells, keratinocytes and hair follicle buds were isolated from wild-type and transgenic skin and cultured in 0.05 mM Ca2+ medium that selects for the proliferative K5-expressing population. Transgenic keratinocytes were very sensitive to small concentrations of TPA in vitro, assuming a dendritic morphology that persisted for 6–12 h before cells became rounded and detached from the substrate (Fig. 5A). In contrast, wild-type keratinocytes developed a dendritic shape only transiently and at higher TPA concentrations before reassuming an epithelial morphology. By 6 h, TPA exposure resulted in a dose-dependent decrease in cell number and BrdU incorporation in transgenic keratinocytes (Fig. 5, B and C). At this
time point, the number of cells incorporating BrdU was reduced by >80% in transgenic keratinocytes but <20% in wild-type keratinocytes at the highest TPA dose tested. Together, these results suggested that activation of over-expressed PKCα in keratinocytes resulted in a rapid cell cycle block and cell loss consistent with the in vivo damage to epidermal cells.

In vivo data suggested that before the inflammatory response epidermal and upper hair follicle cells became apoptotic when exposed to TPA. This response was tested directly on transgenic keratinocytes in the in vitro model. MTT assays revealed a TPA dose-dependent loss of cell viability in transgenic, but not wild-type, keratinocytes within 6 h (Fig. 5D). Pretreatment with a PKCα inhibitor, Go6976, prevented cell death in TPA-treated PKCα keratinocytes, confirming that the PKCα activity was responsible for the decrease in cell viability (Fig. 5E). Additional analyses suggested that PKCα activation initiated an apoptotic death pathway (Fig. 6, A and B). By FACS analysis, the number of annexin V-positive cells increased from ~10–40% in TPA-treated transgenic, but not wild-type, keratinocytes. Furthermore, there was a 5-fold increase in the number of attached cells that stained for activated caspasases in PKCα keratinocytes treated with TPA. These results are consistent with the analysis of apoptotic transgenic keratinocytes detected in vivo, and indicate that the observed loss of keratinocytes in vivo is likely to be a direct consequence of PKCα activation independent of the inflammatory response.

**PKCα mediates expression of multiple cytokines and chemokines in keratinocytes**

In the previous description of the TPA-exposed K5PKCα transgenic skin phenotype by Wang and Smart (18), enhanced expression of transcripts for MIP-2 and TNF-α were detected, as well as elevated levels of COX-2 protein. We have confirmed the up-regulation of MIP-2 and COX-2 transcripts by RT-PCR in TPA-treated cultured transgenic keratinocytes (Fig. 7A), and in addition detected strong induction of MIP-3α. We have used the in vitro model to examine expression of other cytokines and chemokines that may contribute to the inflammatory response. RPAs were used to screen for cytokine and chemokine transcripts that might be differentially regulated by PKCα activation in the first 3 h after TPA treatment (Fig. 7B). The detection of TNF-α by this method is consistent with the results of Wang and Smart (18) assayed by Northern blot. In addition, specific up-regulation of MIP-1α and β and IL-12p40, but not IL-18, were detected. In fact, TPA caused a reduction of IL-18 transcripts in transgenic keratinocytes. Of particular interest is the detection, both by RPA (data not shown) and RT-PCR analysis, of CCR1 that is up-regulated by TPA treatment in transgenic keratinocytes. The expression of this receptor and CXCR2 on keratinocytes in an environment where ligands such as MIP-1α and MIP-2 are also up-regulated suggests that an autocrine mechanism may be functioning in the entirety of the keratinocyte response to PKCα activation.

In vitro chemotaxis assays were used to test whether culture supernatant from TPA-treated K5-PKCα keratinocytes contains chemotactic activity. Supernatants from TPA-treated transgenic cells were able to attract neutrophils to a greater extent than supernatants from treated wild-type keratinocytes (Fig. 7C), confirming that functional chemokines are released from keratinocytes after activation of PKCα.

Both CCR1 and CCR5 are the major receptors for MIP-1α, but CCR1 is the dominant receptor for MIP-1α in mouse neutrophils.
Deletion of CCR1 in mice resulted in impaired neutrophil infiltration in several mouse models (24, 30–32). Because MIP-1α is significantly up-regulated in TPA-treated transgenic keratinocytes, we tested whether neutrophil infiltration in the PKCa transgenic mice is mediated by MIP-1α and its receptor CCR1. We crossed K5-PKCa mice with CCR1<sup>−/−</sup> mice, treated bigenic K5-PKCa/CCR1<sup>−/−</sup> mice topically with TPA, and compared the inflammatory response with K5-PKCa/CCR1<sup>+/−</sup> littermates. In both genotypes, intraepidermal inflammation was massive and equivalent (Fig. 8A), suggesting that CCR1 is not a major mediator of neutrophil infiltration in response to PKCa activation. Confirmatory results were obtained using supernatants from TPA-treated K5-PKCa keratinocytes in chemotaxis assays with CCR1<sup>−/−</sup> or CCR1<sup>+/−</sup> neutrophils (Fig. 8B). Whereas recombinant MIP-1α confirmed the requirement for CCR1 to induce chemotaxis for this ligand, and fMet-Leu-Phe confirmed the capability for chemotaxis in neutrophils of both genotypes, conditioned medium from TPA-treated K5-PKCa keratinocytes was equally chemotactic in the presence or absence of CCR1 on the neutrophilic target. Thus, CCR1 is not required for either in vivo or in vitro chemotaxis, and MIP-1α is not likely to be a critical mediator of intraepidermal inflammation in this model.

AP-1 is an effector of PKCa-mediated apoptosis in keratinocytes

Previous data from keratinocytes suggested that PKCa regulation of gene expression in differentiating keratinocytes occurs through a common signal transduction pathway that involves AP-1 activity (12). Similarly, PKC-mediated apoptosis has been linked to AP-1 activation through p38 and Jun kinases (33, 34). To test this link in the PKCa transgenic model, primary keratinocytes from PKCa<sub>2×</sub> TRE-luciferase bitransgenic mice and nontransgenic mice were treated with TPA, and reporter activity was quantified in total cell extracts. TPA treatment induces a strong and sustained increase of AP-1-dependent reporter activity only in the PKCa transgenic keratinocytes (Fig. 9). To test whether this increased AP-1 activity was associated with the TPA-induced apoptotic response, primary keratinocytes from PKCa transgenic mice and nontransgenic mice were transduced with an adenovirus (A-FOS) that expresses a dominant-negative construct for the AP-1 family of transcription factors. The A-FOS mutant dimerizes with Jun family members and prevents DNA binding, as the DNA binding domain of the dominant-negative mutant is replaced with an amphipathic region that is unable to bind to DNA (25, 35). Infection with the A-FOS adenovirus prevented the increase in AP-1-specific DNA binding activity in TPA-treated transgenic keratinocytes (Fig. 9B) and modified the biological effects of PKCa overexpression and activation. Expression of A-FOS prevented cell killing by TPA in PKCa transgenic cells as determined by MTT assay (Fig. 9C). Although an AP-1 binding site is present in the promoter region of the keratin 5 gene (36), A-FOS did not interfere with PKCa transgene expression as determined by immunoblots in A-FOS- or A-CMV-infected transgenic keratinocytes (data not shown).
PKCα-mediated inflammation is independent of AP-1

We generated triple transgenic mice by crossing bigenic mice that carry a tetracycline-regulated, K5-targeted A-FOS construct with the K5-PKCα mice. The triple transgenic mice were TPA treated under conditions of A-FOS expression (without doxycycline), and skin was collected at various time points. Expression of A-FOS did not prevent the intraepidermal inflammatory infiltrate seen in K5-PKCα mice (Fig. 10A). Transgenic A-FOS also did not prevent the destruction of the epidermis or hair follicles that occur as a consequence of the inflammatory infiltrate or the extensive hyperplasia that results during the recovery process (Fig. 10A). Furthermore, A-FOS transduction in transgenic keratinocytes in vitro did not influence chemotactic activity of culture supernatants after TPA treatment (Fig. 10B). This was consistent with the even higher expression of specific chemokines detected by RT-PCR or RPA analysis in A-FOS-transduced, TPA-treated K5-PKCα keratinocytes (Fig. 10C and D). In contrast, A-FOS did reduce expression of COX-2 and CCR1 in TPA-treated transgenic cells (Fig. 10C and D).

Discussion

The K5-PKCα transgenic mouse provides a useful model to explore the influence of this PKC isoform on cutaneous physiology and pathology. We now show that transgenic keratinocytes in vitro are a valid model to explore downstream signaling pathways at the cellular level. As first reported by Wang and Smart (18) for the C57BL/6 background, and now confirmed for the FVB/N background, keratinocyte PKCα is a major mediator of neutrophilic inflammation both in the dermal and epidermal compartments. Wang and Smart demonstrated a role for phospholipase A2 and mitogen-activated protein kinase kinase signaling in the generation of PG (19) that may contribute to inflammation in this model. We now show that activation of PKCα increases expression of multiple cytokines and chemokines and increases chemokine receptor CCR1 transcripts in the keratinocytes themselves. We further show that activation of PKCα in the FVB/N strain produces keratinocyte growth arrest and apoptosis that is dependent on intact AP-1 transcriptional activation, but independent of the inflammatory infiltrate. Likewise, the apoptotic response is not likely to be the direct signal for the inflammatory infiltrate, because substantial apoptosis induced by UVB does not result in intraepidermal inflammation in transgenic skin. Together, it would appear that PKCα controls two distinct responses in keratinocytes, one related to growth and viability that is AP-1-dependent and the other related to chemotaxis and inflammation that appears to be independent of AP-1.

Growth arrest mediated by PKCα overexpression has been previously demonstrated in epithelial cells, including those derived...
PKCα MEDIATES INTRAEPIDERMAL INFLAMMATION

Considerable evidence has accumulated implicating PKCα in keratinocyte apoptosis (11, 41). Those studies indicated a direct role for the δ isoform translocating to mitochondria and acting on a mitochondrial apoptotic pathway to reduce keratinocyte viability. In contrast, PKCα is frequently anti-apoptotic by virtue of its ability to phosphorylate and activate BCL2 in mitochondria (42). However, PKCα is proapoptotic for prostate and gastric cancer cells (43, 44), suggesting that the cell type, physiological state of the target cell, or subcellular distribution of the enzyme determines the response to PKCα activation. In skin, activation of overexpressed PKCα in keratinocytes is proapoptotic, but paradoxically, high constitutive activity of PKCα is characteristic of neoplastic epidermal cells transformed by the ras oncogene (45). Such cells also have increased levels of diacylglycerol, the endogenous activator of PKCα (46). Because the proapoptotic activity of cutaneous PKCα is prevented by blocking the AP-1 pathway, the proximal effectors of apoptosis are likely to be AP-1-regulated genes. The expression of AP-1 factors is altered in neoplastic keratinocytes (14), and this could contribute to the differences in response to PKCα activation between normal and neoplastic keratinocytes. Elevated PKCα activity in neoplastic cells could also contribute to the inflammatory response in cutaneous neoplasms. We cannot exclude a role for TNF-α as a mediator of the apoptosis observed in this model. TNF-α is PKC inducible and proapoptotic when overexpressed in mouse keratinocytes (47), and is highly induced in PKCα transgenic skin. However, TNF-α is not suppressed by A-FOS in PKCα transgenic keratinocytes (Fig. 10). Exogenous TNF-α cannot induce apoptosis in cultured PKCα keratinocytes (C. Cattaisson and S. H. Yuspa, unpublished data). Together, these results suggest that TNF-α is not the mediator of the apoptotic response, but further studies will be required to elucidate the AP-1-dependent pathways altering keratinocyte viability.

The massive intraepidermal inflammatory infiltrate seen after PKCα activation is an unusual finding in a mouse model. Because...
this was detected in both C57BL/6 and FVB/N strains, it is unlikely to be a function of unique genetic modifiers as has been reported for other inflammatory responses (48). PKC activation in mouse skin is commonly associated with a mixed leukocyte dermal inflammation (49), but only occasional leukocytes are detected intraepidermally. Thus, PKC activation must have a unique role in directing neutrophils into the epidermis. We have used an in vitro model to assay for cytokines and chemokines that may contribute to the phenotype by stimulating specific downstream chemokines. IL-12 is known to induce IFN-γ-inducible protein-10 as well as monocyte chemotactic protein-1 and lymphotoxin, and is predominantly a T cell cytokine. Interestingly, IL-12p40 is induced by TNF-α, and conversely, IL-12 suppresses TNF-α in the skin (53, 54). The TNF-α pathway is an interesting candidate to participate in the PKCα-mediated inflammatory response. TNF-α is up-regulated early in induced cutaneous neutrophilic inflammatory responses (55). Genetic deletion of IκBα produced a dermatitis characterized by intraepidermal neutrophilic abscesses and elevation of TNF-α levels in the skin (56, 57). Although targeting TNF-α to the epidermis produced only a mild dermal infiltrate (58) that did not reproduce the IκBα null phenotype, this may reflect an extraordinarily elevated TNF-α level not achieved as a physiological response. The TNF-α/NF-κB pathway then must be considered in the future evaluation of the inflammatory arm of the PKCα response. Semiquantitative RT-PCR analysis suggested two other chemokines for further study. In particular, expression of MIP-2, a mouse homologue of IL-8, was substantially increased in transgenic keratinocytes. IL-8 has been associated with the intraepidermal pustules in psoriasis (59). The receptor for MIP-2, CXCRC2r, is a major chemokine receptor expressed in neutrophils and mediates neutrophilic inflammation. CXCRC2−/− mice have defects in neutrophil recruitment in an acute inflammatory response in several mouse models. Although MIP-2 per se has not been tested by targeting to murine epidermis, skin targeting the homologous chemokine KC, which shares the CXCRC2r, produced only a mild dermal infiltrate in a transgenic model (60). Nevertheless, MIP-2 elevation is detected as an early response to induced neutrophilic inflammation in mouse models and requires further analysis (55). Similarly, MIP-3α, a ligand for CCR6, is elevated in psoriasis and is induced by TNF-α (61). Although MIP-3α is thought to be chemotactic for dendritic cells, its potential role in the acute inflammatory response in this model deserves further study.

The PKCα transgenic mouse model is promising for discovering the underlying trophic interactions that produce intraepidermal inflammation and for testing potential new targets for therapy. In addition to exploring the role of cytokines and chemokines, other studies can address the contribution of chemokine receptors such as CCR1 and others. In the case of CCR1, the bigenic model we developed should be useful to test a potential role for keratinocyte CCR1 in apoptosis or growth regulation, particularly because the microenvironment also contains elevated MIP-1α, responsible for the phenotype, because deletion of its dominant receptor in neutrophils, CCR1, did not reduce the intraepidermal inflammatory infiltrate. MIP-1β is predominantly chemotactic for monocytes, and this was not a predominant cell type in the inflammatory lesions. Two cytokines, IL-12p40 and TNF-α, could contribute to the phenotype by stimulating specific downstream chemokines. IL-12 is known to induce IFN-γ-inducible protein-10 as well as monocyte chemotactic protein-1 and lymphotoxin, and is predominantly a T cell cytokine. Interestingly, IL-12p40 is induced by TNF-α, and conversely, IL-12 suppresses TNF-α in the skin (53, 54). The TNF-α pathway is an interesting candidate to participate in the PKCα-mediated inflammatory response. TNF-α is up-regulated early in induced cutaneous neutrophilic inflammatory responses (55). Genetic deletion of IκBα produced a dermatitis characterized by intraepidermal neutrophilic abscesses and elevation of TNF-α levels in the skin (56, 57). Although targeting TNF-α to the epidermis produced only a mild dermal infiltrate (58) that did not reproduce the IκBα null phenotype, this may reflect an extraordinarily elevated TNF-α level not achieved as a physiological response. The TNF-α/NF-κB pathway then must be considered in the future evaluation of the inflammatory arm of the PKCα response. Semiquantitative RT-PCR analysis suggested two other chemokines for further study. In particular, expression of MIP-2, a mouse homologue of IL-8, was substantially increased in transgenic keratinocytes. IL-8 has been associated with the intraepidermal pustules in psoriasis (59). The receptor for MIP-2, CXCRC2, is a major chemokine receptor expressed in neutrophils and mediates neutrophilic inflammation. CXCRC2−/− mice have defects in neutrophil recruitment in an acute inflammatory response in several mouse models. Although MIP-2 per se has not been tested by targeting to murine epidermis, skin targeting the homologous chemokine KC, which shares the CXCRC2r, produced only a mild dermal infiltrate in a transgenic model (60). Nevertheless, MIP-2 elevation is detected as an early response to induced neutrophilic inflammation in mouse models and requires further analysis (55). Similarly, MIP-3α, a ligand for CCR6, is elevated in psoriasis and is induced by TNF-α (61). Although MIP-3α is thought to be chemotactic for dendritic cells, its potential role in the acute inflammatory response in this model deserves further study.

The PKCα transgenic mouse model is promising for discovering the underlying trophic interactions that produce intraepidermal inflammation and for testing potential new targets for therapy. In addition to exploring the role of cytokines and chemokines, other studies can address the contribution of chemokine receptors such as CCR1 and others. In the case of CCR1, the bigenic model we developed should be useful to test a potential role for keratinocyte CCR1 in apoptosis or growth regulation, particularly because the microenvironment also contains elevated MIP-1α, responsible for the phenotype, because deletion of its dominant receptor in neutrophils, CCR1, did not reduce the intraepidermal inflammatory infiltrate. MIP-1β is predominantly chemotactic for monocytes, and this was not a predominant cell type in the inflammatory lesions. Two cytokines, IL-12p40 and TNF-α, could contribute to the phenotype by stimulating specific downstream chemokines. IL-12 is known to induce IFN-γ-inducible protein-10 as well as monocyte chemotactic protein-1 and lymphotoxin, and is predominantly a T cell cytokine. Interestingly, IL-12p40 is induced by TNF-α, and conversely, IL-12 suppresses TNF-α in the skin (53, 54). The TNF-α pathway is an interesting candidate to participate in the PKCα-mediated inflammatory response. TNF-α is up-regulated early in induced cutaneous neutrophilic inflammatory responses (55). Genetic deletion of IκBα produced a dermatitis characterized by intraepidermal neutrophilic abscesses and elevation of TNF-α levels in the skin (56, 57). Although targeting TNF-α to the epidermis produced only a mild dermal infiltrate (58) that did not reproduce the IκBα null phenotype, this may reflect an extraordinarily elevated TNF-α level not achieved as a physiological response. The TNF-α/NF-κB pathway then must be considered in the future evaluation of the inflammatory arm of the PKCα response. Semiquantitative RT-PCR analysis suggested two other chemokines for further study. In particular, expression of MIP-2, a mouse homologue of IL-8, was substantially increased in transgenic keratinocytes. IL-8 has been associated with the intraepidermal pustules in psoriasis (59). The receptor for MIP-2, CXCRC2, is a major chemokine receptor expressed in neutrophils and mediates neutrophilic inflammation. CXCRC2−/− mice have defects in neutrophil recruitment in an acute inflammatory response in several mouse models. Although MIP-2 per se has not been tested by targeting to murine epidermis, skin targeting the homologous chemokine KC, which shares the CXCRC2r, produced only a mild dermal infiltrate in a transgenic model (60). Nevertheless, MIP-2 elevation is detected as an early response to induced neutrophilic inflammation in mouse models and requires further analysis (55). Similarly, MIP-3α, a ligand for CCR6, is elevated in psoriasis and is induced by TNF-α (61). Although MIP-3α is thought to be chemotactic for dendritic cells, its potential role in the acute inflammatory response in this model deserves further study.

The PKCα transgenic mouse model is promising for discovering the underlying trophic interactions that produce intraepidermal inflammation and for testing potential new targets for therapy. In addition to exploring the role of cytokines and chemokines, other studies can address the contribution of chemokine receptors such as CCR1 and others. In the case of CCR1, the bigenic model we developed should be useful to test a potential role for keratinocyte CCR1 in apoptosis or growth regulation, particularly because the microenvironment also contains elevated MIP-1α, a ligand for this receptor. However, present data indicate that CCR1 ligands are not responsible for intraepidermal inflammation. If the K5-PKCa mouse is to serve as a model for human disease or therapy of cutaneous inflammation, there should be pathological conditions where PKCa is activated in the skin. The similarity of the inflammatory skin lesions in the PKCa mouse to aspects of human pustular psoriasis has been noted (18), and similar lesions are detected in the spontaneous mouse mutant “flaky skin,” a putative animal model for human psoriasis (62). Additionally, MIP-3α and IL-8/MIF-2 are elevated in some psoriatic lesions, suggesting further similarities (59, 61). Several reports have suggested that PKC signaling is altered in psoriasis (2, 63), and the endogenous PKC
ligand diacylglycerol is elevated in psoriatic lesions but not uninvolved skin (64).

Further studies to address this issue seem warranted. Even in the absence of a specific human pathological homologue, K5-PKCα mice and keratinocytes derived from them will advance our understanding of the important contribution that PKC signaling makes in mediating chemokine expression and cutaneous inflammation. Such understanding is essential to develop rational therapies for cutaneous inflammation.

Acknowledgments
We acknowledge the assistance provided by Jeff Hildesheim for UV irradiation studies, National Cancer Institute/Frederick Cancer Research and Development Center, Pathology Core for special stains, Andrea Pearson for technical help, and Bettie Sugar for editorial assistance. The generous contribution of the K5 promoter cassette from Dr. Jose Jorcano is also acknowledged.

References


